LUND, Sweden, April 28, 2021 /PRNewswire/ -- Immunovia has
today published its interim report for the period January 1 – March 31,
2021. It is available on Immunovia's
website.
Patrik Dahlen, CEO Immunovia:
"Thanks to the great efforts of our employees, we achieved
significant success during Q1 for our blood test IMMray™ PanCan-d.
We reached the final milestone in the development phase and the
next step was to apply for CLIA certification for IMMray™ PanCan-d
to receive market approval in the US. In addition, we have worked
to improve the performance of the test in symptomatic high-risk
patients. We presented new data that show both improved specificity
and sensitivity."
Telephone conference
Investors, analysts and media are invited to a webcasted
telephone conference today at 16:30
CET. Patrik
Dahlen, CEO, will present Immunovia and comment on the
interim report followed by a Q&A session. The presentation will
be held in English.
Sweden: +46850558373
United Kingdom: +443333009267
United States:
+18335268396
Belgium: +3224035851
Denmark: +4578150110
France: +33170750720
Germany: +4969222220377
Norway: +4723963688
Switzerland: +41225805976
Netherlands: +31107129162
Link to the
webcast: https://financialhearings.com/event/13844
Following the telephone conference, a recording will be
available on Immunovia's website (www.immunovia.com).
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 16.00 CET on April 28,
2021.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final
validation study was completed in Q1 2021. Commercial testing will
begin in Q2 after the accreditation of Immunovia Dx
Laboratory in Marlborough,
Massachusetts, USA.
IMMray™ PanCan-d will be the first blood-based test for early
diagnosis of pancreatic cancer on the market, with a potential to
significantly improve patient survival and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-reports-interim-report-january---march-2021,c3335752
The following files are available for download:
https://mb.cision.com/Main/13121/3335752/1409160.pdf
|
Immunovia Interim
Report, January-March 2021
|
https://news.cision.com/immunovia-ab/i/key-indicators,c2906484
|
Key
Indicators
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-reports-interim-report-january--march-2021-301279222.html
SOURCE Immunovia AB